- DVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $82.8 million.
- DVA is down 3.2% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in DVA with the Ticky from Trade-Ideas. See the FREE profile for DVA NOW at Trade-Ideas More details on DVA: DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. DVA has a PE ratio of 28. Currently there are 6 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for DaVita HealthCare Partners has been 1.6 million shares per day over the past 30 days. DaVita HealthCare has a market cap of $13.1 billion and is part of the health care sector and health services industry. The stock has a beta of 0.69 and a short float of 1.8% with 2.56 days to cover. Shares are down 8.7% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Highlights from the ratings report include:
- DAVITA HEALTHCARE PARTNERS has improved earnings per share by 17.6% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, DAVITA HEALTHCARE PARTNERS increased its bottom line by earning $3.34 versus $2.90 in the prior year. This year, the market expects an improvement in earnings ($3.77 versus $3.34).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 17.2% when compared to the same quarter one year prior, going from $184.12 million to $215.87 million.
- Despite its growing revenue, the company underperformed as compared with the industry average of 9.4%. Since the same quarter one year prior, revenues slightly increased by 8.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The gross profit margin for DAVITA HEALTHCARE PARTNERS is currently lower than what is desirable, coming in at 29.06%. Regardless of DVA's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, DVA's net profit margin of 6.12% compares favorably to the industry average.
- Currently the debt-to-equity ratio of 1.84 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Regardless of the company's weak debt-to-equity ratio, DVA has managed to keep a strong quick ratio of 1.72, which demonstrates the ability to cover short-term cash needs.
- You can view the full DaVita HealthCare Partners Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.